Skip to content
Clinical Trials – home

Hospital Clinico San Carlos

Verified siteinfo

Spain Calle Del Profesor Martin Lagos Sn, 28040 Madrid, Spain

  • 205 trials recruiting
  • Non-small cell lung cancer · Breast cancer · Breast cancer metastatic
  • Adults and children

About Specializations

Hospital Clinico San Carlos in Madrid, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Breast cancer metastatic, Bladder cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms – Medical Oncology

The Medical Oncology department at Hospital Clinico San Carlos focuses on advanced research in neoplastic diseases, particularly targeting patients with EGFR‑mutant non‑small cell lung cancer who have progressed after standard EGFR‑TKI therapy.

  • Evaluating new combination regimens with immunotherapy and chemotherapy
  • Assessing overall survival benefits
  • Measuring progression‑free survival using standardized imaging criteria

These studies aim to improve treatment options for individuals with advanced lung cancer, offering hope for longer survival and better quality of life while reinforcing the site’s role as a leading non‑commercial research center in Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle Del Profesor Martin Lagos Sn28040 MadridSpain
Recruiting now
205 trials
Conditions studied
303
Partner status
Verified site

More sites in MadridSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

554 clinical trials

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Agitation+1

Recruiting

A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dextromethorphan Hydrobromide

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of VENT-03 tablets in adults with active cutaneous lupus erythematosus with or without systemic lupus erythematosus

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:VENT-03
  • Sponsor:Ventus Therapeutics U.S. Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.